• New Mexico had the 12th highest drug overdose death rate in the nation in 2016. Naloxone is a safe and effective medication that reverses the effects of prescription opioids and heroin, thereby preventing opioid overdose death. 
• The risk of opioid overdose is statewide, with the highest death rates among people aged 35-54 and in rural areas. 
• In 2016, Senate Bill 262/House Bill 277 was signed and the naloxone Statewide Standing Order for Pharmacists was written, which allows all registered pharmacists to dispense naloxone to any person who uses an opioid or any person in a position to assist a person at risk of experiencing an opioid overdose. The state Medicaid plan was expanded to include coverage of intranasal naloxone. Pharmacies are being trained on the naloxone standing order and billing procedures. In FY17, 60.9% of retail pharmacies statewide dispensed naloxone products.
• In FY2018 73% of the retail pharmacies statewide dispensed naloxone products.
• Retail pharmacies that do not submit any naloxone claims to Medicaid will continue to be identified and contacted as to their reasons for not submitting claims and/or willingness to stock and dispense. 

• NMDOH
• New Mexico Board of Pharmacy
• New Mexico Human Services Department
• New Mexico Pharmacists’ Association
• Local community and chain pharmacies and pharmacists
• Local managed care organizations and insurance payers
• Pharmacy wholesalers  
• University of New Mexico College of Pharmacy
• Southwest CARE Center Pharmacy

• Removing barriers to pharmacy-based naloxone dispensing practices.
• Implementing naloxone standing orders.
• Training pharmacies on naloxone and the standing order.
• Collaborating with state managed care organizations, and other insurers, to add naloxone products to their drug formularies.
• Peer-to-peer and community engagement with stakeholders to assist NMDOH in overdose prevention efforts, such as pharmacy-based naloxone.

• Remove barriers to pharmacy-based naloxone dispensing practices, such as ensuring adequate pharmacy reimbursement for naloxone, removing extra training requirements for pharmacists, and working on stigma reduction.
• Work with managed care organizations, and other insurers, to include naloxone products, and reducing restrictions on those products, on all pharmacy benefit drug formularies.
• Conduct peer-to-peer outreach to pharmacists through large chain pharmacies, professional pharmacist associations, and the University of New Mexico College of Pharmacy.

• Q1:  Identify pharmacies that are not submitting Medicaid claims for naloxone and develop plan to contact. Incomplete - Identified that 234 of the 369 known pharmacies (63%) submitted Medicaid claims for naloxone. Plan of contact being drafted.
• Q2: Contact pharmacies that did not submit Medicaid claims for naloxone from Q1 and identify pharmacies that are not submitting Medicaid claims for Q2.
• Q3: Contact pharmacies that did not submit Medicaid claims for naloxone from Q2 and identify pharmacies that are not submitting Medicaid claims for Q3.
• Q4: Contact pharmacies that did not submit Medicaid claims for naloxone from Q3 and identify pharmacies that have not submitted Medicaid claims for Q4 and contact.

Despite not achieving anticipated results for the 1st quarter of FY18, the Prescription Drug Overdose Prevention Program (PDOPP) achieved and exceeded results for Q2, Q3 and Q4.  Overall for FY18, 72.6% of retail pharmacies dispensed naloxone, which exceeds the performance target. PDOPP has many other program activities currently operating along with this performance measure to address and lessen the overdose death rate due to opioids.  With FY18 ending and FY19 starting, PDOPP is continually engaged in many well established program activities and partnerships while establishing evidence-based new ones to effectively address the evolving drug overdose burden in New Mexico.  Pharmacies not currently providing naloxone have been surveyed and the individually encouraged to start providing naloxone.